Braidwell’s RAPT Therapeutics RAPT Stock Holding History

Braidwell’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-929,694	Closed	-$31.5M	–	96
2025 Q4	$31.5M	Buy	+929,694	New	+$28.9M	1.01%	40
2024 Q1	–	Sell	-48,663	Closed	-$9.67M	–	79
2023 Q4	$9.67M	Sell	48,663 -86,651	-64%	-$10.7M	0.36%	61
2023 Q3	$18M	Buy	135,314 +12,264	+10%	+$2M	0.57%	60
2023 Q2	$18.4M	Buy	+123,050	New	+$19.2M	0.6%	56
2023 Q1	–	Sell	-125,000	Closed	-$19.8M	–	95
2022 Q4	$19.8M	Buy	+125,000	New	+$20M	0.66%	53

Braidwell's RAPT Position: Q1 2026 in Review

Braidwell sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 929,694 shares — an estimated $31.5M sold.

Braidwell first reported a position in RAPT in Q4 2022 and held it in 5 quarters. The position peaked at $31.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Braidwell reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Braidwell sold 929,694 RAPT Therapeutics shares in Q1 2026, an estimated $31.5M.
Braidwell first reported a position in RAPT Therapeutics in Q4 2022 and held it in 5 quarters.
Braidwell's RAPT Therapeutics position peaked at $31.5M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.